Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients: A Multicenter Analysis

Documenti analoghi

• Sleep Disturbance and Related Factors in the Patients with Relapsing‐Remitting Multiple Sclerosis
  di: Izabela Sempik, et al.
  Pubblicazione: (2024)
• De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria
  di: Michael Guger, et al.
  Pubblicazione: (2025)
• MR Susceptibility Separation for Quantifying Lesion Paramagnetic and Diamagnetic Evolution in Relapsing–Remitting Multiple Sclerosis
  di: Ziyan Zhu, et al.
  Pubblicazione: (2024)
• Cost‐Effectiveness of Dimethyl Fumarate Versus Teriflunomide in Patients With Relapsing‐Remitting Multiple Sclerosis (RRMS) in Iran
  di: Maryam Poursadeghfard, et al.
  Pubblicazione: (2026)
• A Patient‐Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis
  di: Chad Smith, et al.
  Pubblicazione: (2026)